Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;43(2):191-199.
doi: 10.1055/s-0036-1585077. Epub 2016 Jul 29.

α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke

Guy L Reed  1 , Aiilyan K Houng  1 , Satish Singh  1 , Dong Wang  1
Affiliations
Review

α2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke

Guy L Reed et al. Semin Thromb Hemost. 2017 Mar.

Abstract

Thrombotic vascular occlusion is the leading cause of ischemic stroke. High blood levels of α2-antiplasmin (a2AP), an ultrafast, covalent inhibitor of plasmin, have been linked in humans to increased risk of ischemic stroke and failure of tissue plasminogen activator (tPA) therapy. Consistent with these observations, a2AP neutralizes the therapeutic benefit of tPA therapy in experimental stroke. In addition, a2AP has deleterious, dose-related effects on ischemic brain injury in the absence of therapy. Experimental therapeutic inactivation of a2AP markedly reduces microvascular thrombosis, ischemic brain injury, brain swelling, brain hemorrhage, and death after thromboembolic stroke. These data provide new insights into the critical importance of a2AP in the pathogenesis of ischemic brain injury and suggest that transiently inactivating a2AP may have therapeutic value in ischemic stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effects of a2AP-inactivation on outcomes in experimental ischemic stroke. See text for details. *Reed GL, Houng AK, Singh S, unpublished data.
See this image and copyright information in PMC

References

    1. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem. 1976;69(1):209–216. - PubMed
    1. Moroi M, Aoki N. Isolation characterization of alpha2-plasmin inhibitor from human plasma A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem. 1976;251(19):5956–5965. - PubMed
    1. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J. 1976;159(3):545–553. - PMC - PubMed
    1. Edy J, Collen D. The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin. Biochim Biophys Acta. 1977;484(2):423–432. - PubMed
    1. Aoki N, Moroi M, Matsuda M, Tachiya K. The behavior of alpha2-plasmin inhibitor in fibrinolytic states. J Clin Invest. 1977;60(2):361–369. - PMC - PubMed

Substances